| Today's Big NewsJan 12, 2023 |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now.
|
|
| By Dave Muoio The three-day strike over wages and staffing ratios involved more than 7,000 union nurses across the two large New York City hospitals. |
|
|
|
By Kevin Dunleavy In its 11th annual list of Drugs to Watch, data analytics company Clarivate picks 15 which were launched in the U.S. last year or likely to be approved in 2023. In addition to identifying drugs destined for blockbuster status, Clarivate also selected treatments that have the “potential to transform treatment paradigms.” |
By Nick Paul Taylor Sanofi has thrown its financial weight behind its venture capital unit, making a $750 million, multi-year commitment to enable the financier to build on a year in which it backed 10 companies globally. |
By Robert King CMS plans to unveil the first 10 Medicare Part D drugs that will be subject to price negotiation by Sept. 1. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now.
|
|
By Conor Hale In an email to employees that was also published by the company as a blog post, CEO Stephen Gillett said Verily would no longer pursue multiple lines of business. |
By Angus Liu We sat down with GSK's chief commercial officer Luke Miels on the sidelines of JPM. A wide range of topics were discussed, including GSK's anticipated RSV fight with Pfizer, mRNA COVID-flu vaccine opportunity, recent oncology setbacks' impact, an upcoming FDA decision for daprodustat, and the company's M&A appetite. |
By Gabrielle Masson Novartis' Chief Medical Officer Shreeram Aradhye, M.D., is back after a muscle-building stint in biotech, jumping into 2023 laser-focused on five therapeutic areas and driven by the company’s goal of becoming a top U.S. drugmaker. |
By Andrea Park As biotech and pharma have grown in prominence at the annual J.P. Morgan Healthcare Conference, it begs the question of where medtech makers fit in at the meeting—if at all. |
By Paige Minemyer SAN FRANCISCO—Insurtechs have proven to be one of the more volatile segments of the health insurance industry, and it's with that backdrop that executives at several companies took the stage the J.P. Morgan Healthcare Conference on Wednesday afternoon. |
By Zoey Becker After two years of getting on its feet, Viatris is making moves to grow in ophthalmology, with aims to pull down $1 billion in eye care sales by 2028. |
By Conor Hale Instead of training a program to mimic human conversations, Nvidia’s collaboration with the software developer InstaDeep and the Technical University of Munich worked to feed AI models genetic data. |
By Eric Sagonowsky As Teva’s new CEO Richard Francis settles into his role, he’s already sharing thoughts on strategic priorities just days into the job. |
By Ben Adams As AbbVie moved away from promotional spend on its aging mega blockbuster Humira at the same time Sanofi and Regeneron stepped up their TV campaigns for Dupixent in 2021, you might be forgiven for thinking that AbbVie was content to no longer top the annual largest TV drug ad spending lists. |
By Nick Paul Taylor Oramed Pharmaceuticals’ dream of developing an oral insulin for type 2 diabetes looks to be over. With the candidate failing to beat placebo in a phase 3 trial, the biotech outlined plans to stop development and sent its share price tumbling in the process. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
